Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 7
Submit an article Journal homepage
641
Views
7
CrossRef citations to date
0
Altmetric
Original Article: Clinical

The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis

Stefano MolicaDepartment of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy; Correspondence[email protected]
,
Diana GiannarelliBiostatistic Unit, IRCCS Regina Elena, Rome, Italy;
,
Rosanna MirabelliDepartment of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy;
,
Luciano LevatoDepartment of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy;
&
Tait D. ShanafeltDepartment of Medicine, Division of Hematology, Stanford University, Stanford, CA, USA
Pages 1644-1649 | Received 13 Sep 2018, Accepted 26 Oct 2018, Published online: 05 Dec 2018

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Stefano Molica, Valentina Gianfelici & Luciano Levato. (2020) Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib. Expert Opinion on Emerging Drugs 25:1, pages 25-35.
Read now

Articles from other publishers (6)

Oluwatobi Odetola & Shuo Ma. (2023) Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Current Hematologic Malignancy Reports.
Crossref
Neda Alrawashdh, Ali McBride, Brian Erstad, Joann Sweasy, Daniel O. Persky & Ivo Abraham. (2022) Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia. Value in Health 25:10, pages 1685-1695.
Crossref
Monia Marchetti, Paolo Rivela, Claudia Bertassello & Manuela Canicattì. (2022) Comparative Clinical Value of Pharmacologic Therapies for B-Cell Chronic Lymphocytic Leukemia: An Umbrella Analysis. Journal of Clinical Medicine 11:7, pages 1868.
Crossref
John F. Seymour. (2022) Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i. Blood Advances 6:4, pages 1365-1370.
Crossref
Stefano Molica, John F. Seymour & Aaron Polliack. (2021) A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents. Hematological Oncology 39:5, pages 595-604.
Crossref
Xiaoya Yun, Ya Zhang & Xin Wang. (2020) Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia. Biomarker Research 8:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.